Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division
BUFFALO, N.Y. and HONG KONG, April 26, 2016 /PRNewswire/ -- Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.
Prior to joining Athenex, Mr. Yordon was founder, Chairman and CEO of Sagent Pharmaceuticals. Prior to Sagent, he was the Founder and Chief Operating Officer of American Pharmaceutical Partners, an operating division of Abraxis Bioscience prior to its sale to Fresenius Kabi. Mr. Yordon has successfully taken four companies public in the United States and in 2011, was named an Ernst & Young Entrepreneur of the Year and inducted into the Chicago Entrepreneur Hall of Fame. Mr. Yordon has also been recognized for his business innovation and was recently appointed to the Chicago Innovation Council.
Dr. Johnson Lau, Athenex Chief Executive Officer and Chairman commented, "Jeff has had a long standing and successful pharmaceutical career creating significant value for shareholders. His reputation, global relationships and significant marketing and sales experience are a tremendous addition to Athenex. We are delighted to have someone with his extensive credentials join the team, our Board warmly welcomes him."
Mr. Jeffrey Yordon stated, "I have reviewed the landscape in the pharmaceutical sector for the last year and concluded Athenex is one of the most exciting companies in the sector with a great pipeline, strong management, and a vision I share for the future. In addition, their oncology drug pipeline will yield greater opportunities for combination therapies to existing products on the market. I am thrilled to be a member of their management team and look forward to making significant contributions to their success in the future."
Mr. Flint Besecker, Athenex Chief Operating Officer and Board Director commented, "We are excited to have Jeff join the leadership team. His experience using innovation to drive products to market, including his operating knowledge in China, fits nicely with our existing strategy and platform. From a strategic perspective, our newly formed Specialty Products Division will be very complementary to our existing oncology ecosystem. This operating unit will add products which are used in combination with our innovative drug candidates or therapeutically important to cancer patients. This platform will add another lever to drive growth for our shareholders."
About Athenex, Inc.
Founded in 2003, Athenex is an innovative oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies with a particular emphasis on the China and U.S. markets. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. The Athenex business includes: three portfolios of innovative proprietary products under development, medical technology research innovation centers, product development and regulatory teams and existing manufacturing facilities in China and the U.S. Athenex employees include several hundred dedicated professionals to the mission of improving the lives of cancer patients throughout the world. With a connected ecosystem, including an innovation, development and manufacturing presence concentrated in China and the US, Athenex can identify, develop, and deliver unique medical technology across continents and multiple regulatory environments. Athenex has offices throughout the United States and Greater China regions.
For more information about our portfolio of proprietary products and clinical studies, please visit www.athenex.com
SOURCE Athenex, Inc.
Share this article